Related Experiment Video
Updated: Jan 15, 2026
Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
Prognostic Significance of CK5/6 and GATA3 Expression in Recurrent Urothelial Carcinoma
Marzena Lenda-Petrykowska1, Violetta Sulżyc-Bielicka2, Wojciech Dobrzycki3
1Department of Vascular, General and Angiological Surgery, University Clinical Hospital No.2, Pomeranian Medical University in Szczecin, 72 Powstańców Wlkp. Al., 70-111 Szczecin, Poland.
Background/Objectives:
The study aimed to determine whether the expression of CK5/6 and GATA3 is altered in UCa recurrences and to evaluate disease-free survival (DFS) and overall survival (OS) according to CK5/6 and GATA3 expression.
Methods:
A retrospective study was performed in 77 patients with UCa. Surgery was performed in 35 patients. UCa recurrence was observed in 75% of patients. An immunohistochemical assessment of CK5/6 and GATA3 was performed in the primary and recurrent UCa groups.
Results:
CK5/6(+) in primary UCa was associated with a 73% probability of CK5/6(+) recurrence (p = 0.000005) and incidence at a younger age. CK5/6(-) in primary UCa was associated with an 84% probability of CK5/6(-) recurrence (p = 0.000005) and incidence at older age. A higher probability of UCa GATA3(+) recurrence was a significant independent factor associated with longer OS (p = 0.015). A greater probability of UCa CK5/6(+) recurrence was a significant independent factor associated with shorter OS (p = 0.044). Patients with CK5/6(+)-only UCa recurrences had significantly worse OS compared to UCa patients with at least one CK5/6(-) recurrence.
Conclusions:
1. CK5/6 and GATA3 in UCa recurrences may differ from CK5/6 and GATA3 expression in primary UCa. Intensified oncological surveillance is suggested for patients with recurrent CK5/6(+) 2. Patients with at least one UCa CK5/6(-) recurrence have better prognosis compared to patients with only CK5/6(+) recurrences.
